Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Clinical  ·  Weekly Digest - 26 December to 02 January 2026
Junshi Biosciences EGFR-HER3 bispecific antibody ADC has successfully advanced to its global Phase 2 clinical trial, ranking second in the world

Weekly Digest – January 2026 Weekly Digest – January 2026 26 December 2025: Junshi Biosciences EGFR-HER3 bispecific antibody ADC has successfully advanced to its global Phase 2 clinical trial, ranking second in the world Junshi Biosciences has recently registered a […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 26 December to 02 January 2026
Senhwa Biosciences aims at multi-billion dollar global market with CX-5461 combined with ADC “blockbuster” therapy

Weekly Digest – January 2026 Weekly Digest – January 2026 28 December 2025: Senhwa Biosciences aims at a multi-billion dollar global market with CX-5461 combined with ADC “blockbuster” therapy Senhwa Biosciences announced a Phase 1 clinical trial evaluating its first-in-class […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 26 December to 02 January 2026
Harbour BioMed enters into long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates

Weekly Digest – January 2026 Weekly Digest – January 2026 29 December 2025: Harbour BioMed enters into long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates Harbour BioMed entered a long-term strategic collaboration with Yantai Lannacheng Biotechnology to […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 26 December to 02 January 2026
BioAtla and GATC health announce a $40 million special purpose vehicle (SPV) transaction to advance Ozuriftamab Vedotin (Oz-V) into a registrational trial for 2L+ oropharyngeal squamous cell carcinoma (OPSCC)

Weekly Digest – January 2026 Weekly Digest – January 2026 31 December 2025: BioAtla and GATC health announce a $40 million special purpose vehicle (SPV) transaction to advance Ozuriftamab Vedotin (Oz-V) into a registrational trial for 2L+ oropharyngeal squamous cell […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 20 December to 26 December 2025
Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

Weekly Digest – December 2025 Weekly Digest – December 2025 25 December 2025: Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer following disease progression after one or more […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 20 December to 26 December 2025
GSK Korea, first approval of multiple myeloma treatment ‘Blenrep’ ADC

Weekly Digest – December 2025 Weekly Digest – December 2025 23 December 2025: GSK Korea, first approval of multiple myeloma treatment ‘Blenrep’ ADC GSK Korea received regulatory approval from Korea’s Ministry of Food and Drug Safety for Blenrep (Belantamab mafodotin), […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 20 December to 26 December 2025
Enhertu granted breakthrough therapy designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: Enhertu granted breakthrough therapy designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received its tenth FDA Breakthrough […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 20 December to 26 December 2025
PeptiDream announces FDA clearance of IND applications for Phase 1 clinical trials of 225Ac-PD-32766 and 64Cu-PD-32766 in patients with kidney cancer

Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: PeptiDream announces FDA clearance of IND applications for Phase 1 clinical trials of 225Ac-PD-32766 and 64Cu-PD-32766 in patients with kidney Cancer PeptiDream received U.S. Food and Drug […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 20 December to 26 December 2025
Simcere Zaiming builds exclusive partnership with Ipsen for Simcere Zaiming’s innovative antibody drug conjugate

Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: Simcere Zaiming builds exclusive partnership with Ipsen for Simcere Zaiming’s innovative antibody drug conjugate Simcere Zaiming and Ipsen entered an exclusive licensing partnership granting Ipsen global rights outside Greater China to develop, manufacture, and […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 20 December to 26 December 2025
Tongyi Pharmaceuticals announced that it has entered into an exclusive licensing agreement with MultiValent Biotherapies for CBP-1018, a peptide-drug conjugate for the treatment of prostate cancer

Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: Tongyi Pharmaceuticals announced that it has entered into an exclusive licensing agreement with MultiValent Biotherapies for CBP-1018, a peptide-drug conjugate for the treatment of prostate cancer Tongyi Pharmaceuticals entered an […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous252627282930313233Next ›Last »
Page 29 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id